C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky,Christian Dittrich,Ignacio Duran,Satinder Jagdev,Frederick Millard,Christopher Sweeney,Dean F. Bajorin,Linda Cerbone,David I. Quinn,Walter M. Stadler,Jonathan E. Rosenberg,Melissa Lochheed,Paramita Sen,Matthew Squires,Michael Shi,Cora N. Sternberg +15 more
TL;DR: Although generally well tolerated, dovitinib has very limited single-agent activity in patients with previously treated advanced UC, regardless of FGFR3 mutation status.
Journal ArticleDOI
Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Fabio Calabrò,Cora N. Sternberg +1 more
TL;DR: It is suggested that neoadjuvant cisplatin-based combination chemotherapy should be considered as a standard of care for patients with muscle-invasive or locally advanced operable bladder cancer and in patients who are either unfit for or refuse radical cystectomy.
Journal ArticleDOI
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
Evan Y. Yu,Christophe Massard,Mitchell E. Gross,Michael A. Carducci,Stéphane Culine,Gary R. Hudes,Edwin M. Posadas,Cora N. Sternberg,George Wilding,Geralyn C. Trudel,Prashni Paliwal,Karim Fizazi +11 more
TL;DR: Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules, and these data support additional study of dasatinIB for metastatic CRPC.
Journal ArticleDOI
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
Julie N. Graff,Julie N. Graff,Giulia Baciarello,Andrew J. Armstrong,Celestia S. Higano,Peter Iversen,Thomas W. Flaig,David Forer,Teresa Parli,De Phung,Bertrand Tombal,Tomasz M. Beer,Cora N. Sternberg +12 more
TL;DR: Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS and were well tolerated in the elderly subgroup and those aged <75 years, and age and enzyme treatment were associated with a higher incidence of falls.
Journal ArticleDOI
Current therapies and advances in the treatment of pancreatic cancer.
TL;DR: Current standards of therapy for patients with resectable, advanced and metastatic pancreatic cancer are summarized and second line therapy is increasingly proposed and may even provide survival benefits in the future.